Pages that link to "Q37679135"

The following pages link to Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics (Q37679135):

Displaying 42 items.

• Caenorhabditis elegans as a model for cancer research (Q26828013) (← links)
• The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome (Q28071938) (← links)
• Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics (Q33779249) (← links)
• Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics (Q34311685) (← links)
• Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity (Q34493889) (← links)
• Microbial determinants of biochemical individuality and their impact on toxicology and pharmacology (Q34615534) (← links)
• The microbiota, chemical symbiosis, and human disease (Q34616219) (← links)
• In vitro evidence that phosphatidylcholine protects against indomethacin/bile acid-induced injury to cells (Q35035226) (← links)
• Microbes, microbiota, and colon cancer (Q35120938) (← links)
• Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. (Q35314338) (← links)
• Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids (Q35742169) (← links)
• The Microbiome and Musculoskeletal Conditions of Aging: A Review of Evidence for Impact and Potential Therapeutics (Q35871201) (← links)
• Bidirectional interactions between indomethacin and the murine intestinal microbiota (Q35878003) (← links)
• The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (Q35955534) (← links)
• Glucuronides in the gut: Sugar-driven symbioses between microbe and host (Q36340552) (← links)
• An Atlas of β-Glucuronidases in the Human Intestinal Microbiome. (Q38746100) (← links)
• Gut microbiome interactions with drug metabolism, efficacy, and toxicity (Q38945423) (← links)
• Chemical transformation of xenobiotics by the human gut microbiota. (Q39392651) (← links)
• Ciprofloxacin blocked enterohepatic circulation of diclofenac and alleviated NSAID-induced enteropathy in rats partly by inhibiting intestinal β-glucuronidase activity (Q41871344) (← links)
• Nonsteroidal Anti-Inflammatory Drug-Induced Leaky Gut Modeled Using Polarized Monolayers of Primary Human Intestinal Epithelial Cells. (Q44876695) (← links)
• Check your microbiota when taking the drug (Q46117153) (← links)
• Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity. (Q46403916) (← links)
• Role of enterohepatic recirculation in drug disposition: cooperation and complications (Q46578287) (← links)
• Structural basis for the regulation of β-glucuronidase expression by human gut Enterobacteriaceae (Q47263968) (← links)
• Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs. (Q48226113) (← links)
• The role of gut microbiota in the modulation of drug action: a focus on some clinically significant issues (Q50054146) (← links)
• Three structurally and functionally distinct β-glucuronidases from the human gut microbe Bacteroides uniformis (Q57289642) (← links)
• Dietary metabolism, the gut microbiome, and heart failure (Q58586657) (← links)
• Gut Microbial β-Glucuronidase Inhibition via Catalytic Cycle Interception (Q59770045) (← links)
• Structure, function, and inhibition of drug reactivating human gut microbial β-glucuronidases (Q61443080) (← links)
• Microbiota alter metabolism and mediate neurodevelopmental toxicity of 17β-estradiol (Q64062964) (← links)
• Drug-gut microbiota interactions: implications for neuropharmacology (Q67193237) (← links)
• Microbial Glucuronidase Inhibition Reduces Severity of Diclofenac-Induced Anastomotic Leak in Rats (Q88291285) (← links)
• Relationship Between the Gut Microbiome and Systemic Chemotherapy (Q89565165) (← links)
• Self-reinoculation with fecal flora changes microbiota density and composition leading to an altered bile-acid profile in the mouse small intestine (Q89684694) (← links)
• Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy (Q90316025) (← links)
• Therapeutic significance of β-glucuronidase activity and its inhibitors: A review (Q91961365) (← links)
• Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice (Q92307079) (← links)
• Epithelial delamination is protective during pharmaceutical-induced enteropathy (Q92482341) (← links)
• Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics (Q94560881) (← links)
• Thiazolidin-2-cyanamides derivatives as novel potent Escherichia coli β-glucuronidase inhibitors and their structure-inhibitory activity relationships (Q99414732) (← links)
• Protective effect of naringin on small intestine injury in NSAIDs related enteropathy by regulating ghrelin/GHS-R signaling pathway (Q104492522) (← links)